Ginkgo Bioworks Holdings Inc. (NYSE:DNA) saw an upside of 2.47% to close Monday at $1.66 after adding $0.04 on the day. The 5-day average trading volume is 19,537,621 shares of the company’s common stock. It has gained $1.8600 in the past week and touched a new high 1 time within the past 5 days. An average of 21,244,596 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 23,246,648.
DNA’s 1-month performance is -30.25% or -$0.7200 on its low of $1.5500 reached on 08/18/23. The company’s shares have touched a 52-week low of $1.12 and high of $3.52, with the stock’s rally to the 52-week high happening on 07/19/23. YTD, DNA has lost -1.78% or -$0.0300 and has reached a new high 9 times. However, the current price is down -52.84% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
DNA stock investors last saw insider trading activity on Aug 17.Kelly Jason R () most recently sold 100,000 shares at $1.64 per share on Aug 17. This transaction cost the insider $163,800. 10% Owner, Canton Barry, sold 37,650 shares at a price of $1.64 on Aug 17. Then, on Aug 17, Shetty Reshma P. sold 37,650 shares at a price of $1.64 per share. This transaction amounted to $61,708.
Valuation Metrics
DNA stock has a beta of 1.35. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 10.01 while the price-to-book (PB) in the most recent quarter is 2.13.
Ginkgo Bioworks Holdings Inc.’s quick ratio for the period ended June 29 was 7.50, with the current ratio over the same period at 7.50. In terms of profitability, the gross margin trailing 12 months is 70.70%. The trailing 12-month EBITDA margin is -439.66%. The firm’s gross profit as reported stood at $273.49 million against revenue of $477.71 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected DNA to announce -$0.08 per share in earnings in its latest quarter, but it posted -$0.09, representing a -12.50% surprise. EBITDA for the quarter stood at more than -$165.93 million. DNA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 788.41 million, with total debt at $410.94 million. Shareholders hold equity totaling $1.98 billion.
Let’s look briefly at Ginkgo Bioworks Holdings Inc. (DNA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 21 August was 33.50% to suggest the stock is trending Neutral, with historical volatility in this time period at 87.30%.
The stock’s 5-day moving average is $1.6580, reflecting a -7.26% or -$0.1300 change from its current price. DNA is currently trading -27.19% above its 20-day SMA, +38.33% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -5.68% and SMA200 by-39.42%.
Stochastic %K and %D was 8.75% and 7.53% and the average true range (ATR) pointed at 0.1601. The RSI (14) points at 38.40%, while the 14-day stochastic is at 15.28% with the period’s ATR at 0.1657. The stock’s 9-day MACD Oscillator is pointing at -0.1156 and -0.2264 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Ginkgo Bioworks Holdings Inc. (NYSE: DNA), Goldman downgraded it to a Sell rating. They previously had a Neutral rating on the stock. Analysts offering their rating for DNA stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate DNA as a “sell,”, while 2 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
